BioNTech founders hopeful of a cancer vaccine within a decade
Scientists are hopeful of an mRNA based vaccine for cancer
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Scientists are hopeful of an mRNA based vaccine for cancer
HQ Team October 17, 2022: Biocon Biologics, a subsidiary of India’s Biocon, has inked an out-licencing pact with Japan’s Yoshindo Inc for selling.
FDA confirms Adderall shortage due to problems in Teva Pharma's supply pipeline
Moderna’s mRNA vaccine is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma
Neumora Therapeutics raises $650 million to date to revolutionize treatment of brain diseases
Evgen Pharma and Stalicla sign a $165 million licensing deal for neuro development disorder SFX-01 asset
Merck's Covid-19 pill no help in reducing hospitalization or death, Astrazenaca's nasal spray too fails trial
HQ team October 12, 2022: Marksans Pharma, a listed company, is set to acquire a manufacturing site of Tevapharm, an Indian subsidiary of.
Cipla, an Indian pharmaceutical company, has joined the World Economic Forum’s Lighthouse network to adopt advanced fourth-industrial revolution technologies to transform operations digitally.
HT team October 11, 2022: The Competition Commission of India, the country’s anti-trust regulator has given the nod for Platinum Owl to buy.